Login to Your Account



Tarceva Phase III: 'Modest' Benefit In Pancreas Cancer

By Randall Osborne


Tuesday, September 21, 2004
Already strong in lung cancer, Tarceva proved its mettle in a Phase III study combined with gemcitabine as a first-line therapy against pancreatic cancer, meeting the primary endpoint of survival improvement. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription